Betamethasone Acetate Market Growth Outlook to 2035: Demand Accelerates Amid Aging Population – News and Statistics

Report Update: Jul 10, 2026

World Betamethasone Acetate – Market Analysis, Forecast, Size, Trends and Insights

Ends in–
$4,000$4,000
-50% promo · auto-applied at checkout
License:
Limited to one named user
What you get

• Full report in PDF · Excel data package · Word document · Executive presentation
• Email delivery 24/7 any day, weekends and holidays included
• Content copy-paste enabled · printable format
• Unlimited clarification rounds after delivery

Secure checkout via Stripe
G2on G2·Leader · High Performer · Users Love Us
Jul 10, 2026

Betamethasone Acetate Market Forecast Points Higher Toward 2035, Driven by Rising Chronic Disease Prevalence

Abstract

According to the latest IndexBox report on the global Betamethasone Acetate market, the market enters 2026 with broader demand fundamentals, more disciplined procurement behavior, and a more regionally diversified supply architecture

The World Betamethasone Acetate market is positioned for sustained expansion through 2035, supported by the rising global burden of chronic inflammatory and autoimmune conditions. As a synthetic corticosteroid acetate ester, Betamethasone Acetate serves as a critical active pharmaceutical ingredient (API) in injectable suspensions, topical creams, ophthalmic preparations, and oral formulations. The market is mature yet dynamic, characterized by generic dominance, concentrated production hubs in India and China, and evolving regulatory landscapes. Demand is closely tied to the prevalence of rheumatoid arthritis, asthma, severe allergies, dermatoses, and autoimmune disorders, which continue to increase with aging populations and lifestyle factors. The forecast period 2026-2035 anticipates volume growth at a compound annual rate of approximately 5.2%, with injectable formulations outpacing topical segments due to hospital-based treatment protocols for severe respiratory and rheumatologic conditions. Supply remains structurally concentrated, with India and China accounting for an estimated 60-70% of global API capacity, creating import dependence for Europe and the Americas. Price competition from generic manufacturers and volatility in upstream steroid intermediates, particularly diosgenin, compress margins. Regulatory harmonization under ICH Q7 and WHO prequalification raises entry barriers, favoring established compliant producers. Procurement trends shift toward multi-year volume contracts for supply security. This analysis provides a data-driven view of market size, demand architecture, competitive landscape, and regional dynamics to 2035.

The baseline scenario for the Betamethasone Acetate market from 2026 to 2035 projects steady volume growth at a CAGR of 5.2%, with the market index reaching 165 by 2035 (2025=100). This trajectory is underpinned by expanding treatment of chronic inflammatory and autoimmune diseases across an aging global population, particularly in Asia-Pacific and North America. Demand for injectable Betamethasone Acetate formulations is expected to grow at 6-8% annually, driven by hospital-based protocols for severe respiratory conditions and rheumatologic disorders. Topical and ophthalmic segments will grow more modestly at 3-5% annually, constrained by generic saturation and OTC competition. Supply-side dynamics remain dominated by Indian and Chinese API manufacturers, who together hold over 60% of global production capacity. Price competition is intense, with standard pharmaceutical-grade Betamethasone Acetate spot prices ranging between USD 2,500 and USD 3,800 per kilogram in 2026, and expected to remain under pressure due to upstream raw material cost volatility. Regulatory fragmentation across USP, EP, and CP standards increases compliance costs by 15-25% for multi-market producers. The market is witnessing a shift toward multi-year procurement contracts as large generic buyers seek price predictability. Key risks include potential supply disruptions from environmental enforcement in China, geopolitical trade friction, and quality-related manufacturing stoppages. Overall, the market offers stable growth opportunities for established manufacturers with compliant facilities and diversified customer bases.

Demand Drivers and Constraints

Primary Demand Drivers

• Rising prevalence of chronic inflammatory and autoimmune diseases globally
• Aging population increasing demand for corticosteroid therapies
• Growth in hospital-based treatment protocols for severe respiratory conditions
• Expanding access to healthcare in emerging markets
• Increasing use of injectable formulations for rapid anti-inflammatory action
• Regulatory harmonization favoring established compliant manufacturers

Potential Growth Constraints

• Volatility in raw material prices for diosgenin and steroid intermediates
• Intense price competition from generic manufacturers compressing margins
• Regulatory fragmentation across USP, EP, and CP standards increasing compliance costs
• Concentration of production in few facilities in India and China exposing supply chain risks
• Potential substitution by other corticosteroid salts or non-steroidal anti-inflammatory drugs

Demand Structure by End-Use Industry

Injectable Formulations (estimated share: 35%)

Injectable Betamethasone Acetate formulations are the fastest-growing segment, driven by hospital-based treatment protocols for severe respiratory conditions such as asthma exacerbations and COPD, as well as rheumatologic disorders like rheumatoid arthritis and gout. Demand is supported by the increasing prevalence of these conditions in aging populations and the need for rapid, potent anti-inflammatory effects. By 2035, this segment is expected to account for a larger share as healthcare systems prioritize acute care management. Key demand-side indicators include hospital admission rates for respiratory diseases, rheumatology clinic visits, and government healthcare spending on chronic disease management. The shift toward biologic therapies may moderate growth, but corticosteroids remain first-line treatments in many protocols. Current trend: Growing fastest at 6-8% annually.

Major trends: Increasing adoption of prefilled syringes and autoinjectors for convenience, Rising demand for combination therapies with local anesthetics, Expansion of hospital formularies in emerging markets, and Regulatory focus on sterility assurance and particulate matter control

Representative participants: Pfizer Inc, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sandoz International GmbH, and Teva Pharmaceutical Industries Ltd

Topical Preparations (Creams, Ointments) (estimated share: 30%)

Topical Betamethasone Acetate formulations, including creams and ointments, serve a large patient base with dermatological conditions such as eczema, psoriasis, and contact dermatitis. This segment is mature and highly genericized, with growth driven by population growth, increasing skin disease prevalence, and expanding OTC availability in some markets. However, competition from other topical corticosteroids and non-steroidal alternatives limits upside. Demand indicators include dermatology outpatient visits, prescription volumes for topical steroids, and consumer spending on OTC dermatological products. By 2035, growth will be steady but slower than injectables, with market share gradually declining as injectable and targeted therapies expand. Current trend: Moderate growth at 3-5% annually.

Major trends: Shift toward combination products with antifungals or antibiotics, Increasing preference for once-daily formulations for patient compliance, Rising demand for preservative-free and hypoallergenic bases, and Expansion of generic competition in emerging markets

Representative participants: Merck KGaA, Sanofi S.A, Glenmark Pharmaceuticals Ltd, Cipla Ltd, and Sun Pharmaceutical Industries Ltd

Ophthalmic Preparations (estimated share: 15%)

Ophthalmic Betamethasone Acetate formulations, primarily suspensions and ointments, are used to treat inflammatory eye conditions such as uveitis, conjunctivitis, and post-surgical inflammation. This segment benefits from an aging population with higher incidence of ocular diseases and increasing rates of cataract and refractive surgeries. Demand is driven by ophthalmology clinic visits, surgical volumes, and prescription patterns for post-operative care. Growth is supported by the development of preservative-free formulations and sustained-release delivery systems. By 2035, the segment will see moderate expansion, with potential upside from new drug delivery technologies that improve efficacy and patient compliance. Current trend: Steady growth at 4-6% annually.

Major trends: Development of preservative-free single-dosetibiotics for post-surgical prophylaxis, Rising demand for sustained-release formulations to reduce dosing frequency, and Expansion of ophthalmic surgery volumes in emerging markets

Representative participants: Novartis AG (Alcon), AbbVie Inc. (Allergan), Bausch Health Companies Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd

Oral Formulations (Tablets) (estimated share: 12%)

Oral Betamethasone Acetate tablets are used for systemic treatment of inflammatory and autoimmune conditions, including severe allergies, asthma, and rheumatoid arthritis. This segment is mature and faces competition from other oral corticosteroids and newer biologic therapies. Growth is modest, driven by chronic disease prevalence and generic pricing. Demand indicators include prescription volumes for systemic corticosteroids, hospital discharge data, and primary care visits for allergic conditions. By 2035, the segment will experience slow but stable demand, with market share declining slightly as injectable and targeted therapies gain ground. Cost sensitivity in emerging markets supports continued use of oral generics. Current trend: Slow growth at 2-4% annually.

Major trends: Increasing preference for lower-dose regimens to minimize side effects, Competition from newer non-steroidal anti-inflammatory drugs (NSAIDs), Rising use in combination with disease-modifying antirheumatic drugs (DMARDs), and Generic price erosion limiting revenue growth

Representative participants: Pfizer Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V. , Dr. Reddy’s Laboratories Ltd, and Cipla Ltd

Other Formulations (Inhalation, Nasal, Rectal) (estimated share: 8%)

Other Betamethasone Acetate formulations, including inhalation, nasal sprays, and rectal preparations, address specific therapeutic niches such as asthma, allergic rhinitis, and inflammatory bowel disease. This segment is small but benefits from targeted delivery and reduced systemic side effects. Demand is driven by respiratory disease prevalence, allergy seasonality, and gastroenterology referrals. Growth is supported by product innovation in inhalation devices and nasal formulations. By 2035, the segment will grow modestly, with potential for faster expansion if new indications or delivery technologies emerge. Competition from other corticosteroids and biologics in respiratory and gastrointestinal markets limits upside. Current trend: Niche growth at 3-5% annually.

Major trends: Development of combination inhalers with long-acting beta-agonists, Increasing use of nasal sprays for allergic rhinitis in pediatric populations, Rising awareness of inflammatory bowel disease treatments, and Regulatory focus on device performance and dose consistency

Representative participants: GlaxoSmithKline PLC, AstraZeneca PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, and Mylan N.V

Key Market Participants

Interactive table based on the Store Companies dataset for this report

Regional Dynamics

Asia-Pacific (estimated share: 45%)

Asia-Pacific leads the Betamethasone Acetate market with 45% share, driven by large-scale API production in India and China, rising chronic disease prevalence, and expanding healthcare access. India and China together account for 60-70% of global API capacity. Demand growth is supported by aging populations and increasing hospital infrastructure. Regulatory improvements and cost advantages sustain the region’s manufacturing dominance. Direction: Dominant and growing

North America (estimated share: 25%)

North America holds 25% market share, with demand driven by high prevalence of inflammatory conditions, advanced healthcare infrastructure, and strong generic adoption. The US is a major consumer of injectable and topical formulations. Growth is moderate at 3-4% annually, supported by aging demographics and hospital-based treatment protocols. Import dependence on Asian API remains a structural factor. Direction: Stable with moderate growth

Europe (estimated share: 20%)

Europe accounts for 20% of the market, with mature demand in Germany, France, Italy, and the UK. Growth is slow at 2-3% annually, constrained by generic saturation and regulatory costs. Italy has some API production capacity. Demand is driven by chronic disease management and aging populations. Regulatory harmonization under the European Pharmacopoeia supports quality but raises compliance costs. Direction: Stable with slow growth

Latin America (estimated share: 6%)

Latin America represents 6% of the market, with faster growth at 5-7% annually, driven by improving healthcare access, rising chronic disease burden, and generic penetration. Brazil and Mexico are key markets. Import dependence on Asian API is high. Growth is supported by government healthcare programs and expanding hospital networks. Price sensitivity favors generic formulations. Direction: Emerging with faster growth

Middle East & Africa (estimated share: 4%)

Middle East & Africa hold 4% market share, with growth at 4-6% annually, driven by increasing healthcare investment, rising prevalence of inflammatory diseases, and generic imports. The Gulf Cooperation Council (GCC) countries and South Africa are key markets. Import dependence is near total. Growth is supported by hospital expansion and chronic disease management programs, but constrained by limited local production. Direction: Small but growing

Market Outlook (2026-2035)

In the baseline scenario, IndexBox estimates a 5.2% compound annual growth rate for the global betamethasone acetate market over 2026-2035, bringing the market index to roughly 165 by 2035 (2025=100)

Note: indexed curves are used to compare medium-term scenario trajectories when full absolute volumes are not publicly disclosed

For full methodological details and benchmark tables, see the latest IndexBox Betamethasone Acetate market report

This report provides an in-depth analysis of the Betamethasone Acetate market in the world, covering market size, growth trajectory, demand structure, supply capability, trade flows, pricing, competitive landscape, and forecast to 2035

The study is designed for manufacturers, distributors, importers, exporters, investors, procurement teams, advisors, and strategy teams that need a consistent, data-driven view of market dynamics and a transparent analytical definition of the product scope

Product Coverage

This report covers the market for Betamethasone Acetate, a synthetic corticosteroid used primarily in pharmaceutical formulations for its anti-inflammatory and immunosuppressive properties. The scope includes the active pharmaceutical ingredient (API) in various grades, as well as finished dosage forms and related components used in production and delivery systems

Included

• BETAMETHASONE ACETATE API (BULK AND MICRONIZED)
• FINISHED DOSAGE FORMS (INJECTIONS, CREAMS, OINTMENTS, TABLETS)
• COMPONENTS AND MODULES FOR FORMULATION AND DELIVERY SYSTEMS
• INTEGRATED SYSTEMS FOR STERILE MANUFACTURING AND PACKAGING
• CONSUMABLES AND REPLACEMENT PARTS FOR PRODUCTION EQUIPMENT
• UPSTREAM INPUTS AND CRITICAL RAW MATERIALS FOR SYNTHESIS

Excluded

• OTHER BETAMETHASONE SALTS (E.G., BETAMETHASONE VALERATE, BETAMETHASONE DIPROPIONATE)
• NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
• VETERINARY-GRADE CORTICOSTEROIDS
• OVER-THE-COUNTER (OTC) TOPICAL PREPARATIONS WITHOUT BETAMETHASONE ACETATE

Report Coverage and Analytical Modules

The report combines the standard market-statistics backbone with strategic chapters that are useful for commercial planning, sourcing decisions, market entry, competitor monitoring, and portfolio prioritization

• Market size, historical development, and forecast to 2035
• Demand architecture by application, customer group, and buyer behavior
• Supply structure, production role where applicable, sourcing, and value-chain constraints
• Exports, imports, trade balance, import dependence, and key trade corridors
• Price levels, price corridors, specification effects, and commercial pricing logic
• Competitive landscape, company presence, product portfolio focus, and strategic positioning
• Country profiles for world and regional reports, with production role stated only where relevant

Segmentation Framework

The market is segmented into decision-relevant buckets so that demand drivers, pricing logic, supply constraints, and competitive positions can be compared across the same analytical frame

• By product type / configuration: Betamethasone Acetate, Components and modules, Integrated systems, Consumables and replacement parts
• By application / end-use: Industrial automation and instrumentation, Electronics and optical systems, Semiconductor and precision manufacturing, OEM integration and maintenance
• By value chain position: Upstream inputs and critical components, Manufacturing, assembly and quality control, Distribution, integration and channel partners, After-sales service, replacement and lifecycle support

Classification Coverage

The classification coverage encompasses the entire value chain for Betamethasone Acetate, including upstream inputs and critical components, manufacturing, assembly and quality control, distribution, integration and channel partners, as well as after-sales service, replacement and lifecycle support. The report segments the market by product type, application, and value chain stage to provide a comprehensive view of the industry

Geographic Coverage

Coverage includes global totals, major demand markets, production and sourcing hubs, leading exporters and importers, and country profiles for the top national markets

Data Coverage

• Historical data: 2012-2025
• Forecast data: 2026-2035
• Market indicators: value, volume, consumption, production where available, exports, imports, prices, and company landscape

Units of Measure

• Volume: tonnes
• Value: USD
• Prices: USD per tonne

Methodology

The report combines official statistics, trade records, company disclosures, product-level evidence, and analyst validation. Data are standardized, reconciled, and cross-checked to keep market sizing, trade flows, pricing, and forecasts comparable across countries and time periods

• International trade data, including exports, imports, and mirror statistics
• National production, consumption, and industry statistics where available
• Company-level information from public filings, product portfolios, and disclosed operating footprints
• Price series, unit-value benchmarks, and specification-level price signals
• Analyst review, outlier checks, triangulation, and forecast-scenario validation

All indicators are mapped to a consistent product definition and reviewed against the segmentation framework used in the Table of Contents

1. 1. INTRODUCTION

   Report Scope and Analytical Framing

   1. Report Description
   2. Research Methodology and the Analytical Framework
   3. Data-Driven Decisions for Your Business
   4. Glossary and Product-Specific Terms

2. 2. EXECUTIVE SUMMARY

   Concise View of Market Direction

   1. Key Findings
   2. Market Trends
   3. Strategic Implications
   4. Key Risks and Watchpoints

3. 3. MARKET SIZE AND DEVELOPMENT PATH

   Market Size, Growth and Scenario Framing

   1. Market Size: Historical Data (2012-2025) and Forecast (2026-2035)
   2. Growth Outlook and Market Development Path to 2035
   3. Growth Driver Decomposition
   4. Scenario Framework and Sensitivities

4. 4. CATEGORY SCOPE, DEFINITIONS AND BOUNDARIES

   Commercial and Technical Scope

   1. What Is Included and How the Market Is Defined
   2. Market Inclusion Criteria
   3. Product / Category Definition
   4. Exclusions and Boundaries
   5. Distinction From Adjacent Products and Substitute Categories

5. 5. CATEGORY STRUCTURE, SEGMENTATION AND PRODUCT MATRIX

   How the Market Splits Into Decision-Relevant Buckets

   1. By Product Type / Configuration
   2. By Application / End Use
   3. By Customer / Buyer Type
   4. By Channel / Business Model / Technology Platform
   5. Segment Attractiveness Matrix
   6. Product Matrix and Segment Growth Logic

6. 6. DEMAND, CUSTOMER AND CONSUMER ARCHITECTURE

   Where Demand Comes From and How It Behaves

   1. Consumption / Demand by Country or Region: Historical Data (2012-2025) and Forecast (2026-2035)
   2. Demand by End-Use and Buyer Group
   3. Demand by Customer / Consumer Segment
   4. Purchase Criteria, Switching Logic and Adoption Barriers
   5. Replacement, Replenishment and Installed-Base Dynamics
   6. Future Demand Outlook

7. 7. PRODUCTION, SUPPLY AND VALUE CHAIN

   Supply Footprint, Trade and Value Capture

   1. Production by Country
   2. Manufacturing Footprint and Supply Hubs
   3. Capacity, Bottlenecks and Supply Risks
   4. Value Chain Logic and Margin Pools
   5. Route-to-Market and Distribution Structure

8. 8. TRADE, SOURCING AND IMPORT DEPENDENCE

   Trade Flows and External Dependence

   1. Exports by Country
   2. Imports by Country
   3. Trade Balance and Sourcing Structure
   4. Import Dependence and Supply Resilience
   5. Strategic Trade Corridors

9. 9. PRICING, PROMOTION AND COMMERCIAL MODEL

   Price Formation and Revenue Logic

   1. Price Levels and Price Corridors
   2. Pricing by Segment / Specification / Geography
   3. Cost Drivers and Margin Logic
   4. Promotion, Discounting and Procurement Patterns
   5. Revenue Quality and Commercial Levers

10. 10. COMPETITIVE LANDSCAPE AND PORTFOLIO POWER

    1. Market Structure and Concentration
    2. Competitive Archetypes
    3. Segment-by-Segment Competitive Intensity
    4. Portfolio Breadth and Product Positioning
    5. Capability Matrix
    6. Strategic Moves, Partnerships and Expansion Signals

11. 11. GEOGRAPHIC LANDSCAPE AND COUNTRY ROLES

    Where Growth and Supply Concentrate

    1. Core Demand Markets
    2. Core Production Markets
    3. Export Hubs
    4. Import-Reliant Markets
    5. Fastest-Growing Markets
    6. Country Archetypes and Strategic Roles

12. 12. GROWTH PLAYBOOK AND MARKET ENTRY

    Commercial Entry and Scaling Priorities

    1. Where to Play
    2. How to Win
    3. Build vs Buy vs Partner
    4. Route-to-Market Choices
    5. Localization and Capability Thresholds
    6. Entry Risks and Mitigation

13. 13. WHERE TO PLAY NEXT: MOST ATTRACTIVE GROWTH OPPORTUNITIES

    Where the Best Expansion Logic Sits

    1. Most Attractive Product Niches
    2. Most Attractive Customer Segments
    3. Most Attractive Markets for Commercial Expansion
    4. White Spaces and Unsaturated Opportunities
    5. High-Margin and Underpenetrated Pockets
    6. Most Promising Product Adjacencies

14. 14. PROFILES OF MAJOR COMPANIES

    Leading Players and Strategic Archetypes

    1. Leading Manufacturers and Suppliers
    2. Regional Specialists and Challengers
    3. Production Footprint and Manufacturing Capacities
    4. Product Portfolio and Segment Focus
    5. Pricing Positioning and Indicative Price Logic
    6. Channel / Distribution Strength
    7. Strategic Archetypes

15. 15. COUNTRY PROFILES

    Detailed View of the Most Important National Markets

    View detailed country profiles50 countries

16. 16. METHODOLOGY, SOURCES AND DISCLAIMER

    How the Report Was Built

    1. Modeling Logic
    2. Source Register
    3. Publications, Regulatory and Industry References
    4. Analytical Notes
    5. Disclaimer

Loading News content from Store report…
#1

Pfizer Inc

Headquarters
New York, USA
Focus
Pharmaceutical manufacturer
Scale
Global

Major producer of betamethasone acetate products

#2

Merck & Co., Inc

Headquarters
Kenilworth, USA
Focus
Pharmaceutical manufacturer
Scale
Global

Supplies betamethasone acetate in injectable formulations

#3

Sanofi S.A

Headquarters
Paris, France
Focus
Pharmaceutical manufacturer
Scale
Global

Produces betamethasone acetate for anti-inflammatory use

#4

Novartis International AG

Headquarters
Basel, Switzerland
Focus
Pharmaceutical manufacturer
Scale
Global

Markets betamethasone acetate under various brands

#5

Teva Pharmaceutical Industries Ltd

Headquarters
Petah Tikva, Israel
Focus
Generic pharmaceutical manufacturer
Scale
Global

Major generic producer of betamethasone acetate

#6

Mylan N.V. (now

Headquarters
Canonsburg, USA
Focus
Generic pharmaceutical manufacturer
Scale
Global

Supplies betamethasone acetate generics

#7

Sandoz International GmbH

Headquarters
Holzkirchen, Germany
Focus
Generic pharmaceutical manufacturer
Scale
Global

Subsidiary of Novartis; produces betamethasone acetate

#8

Sun Pharmaceutical Industries Ltd

Headquarters
Mumbai, India
Focus
Pharmaceutical manufacturer
Scale
Global

Key Indian producer of betamethasone acetate

#9

Cipla Ltd

Headquarters
Mumbai, India
Focus
Pharmaceutical manufacturer
Scale
Global

Manufactures betamethasone acetate for global markets

#10

Dr. Reddy’s Laboratories Ltd

Headquarters
Hyderabad, India
Focus
Pharmaceutical manufacturer
Scale
Global

Produces betamethasone acetate active pharmaceutical ingredient

#11

Aurobindo Pharma Ltd

Headquarters
Hyderabad, India
Focus
Pharmaceutical manufacturer
Scale
Global

Supplies betamethasone acetate in various dosage forms

#12

Hikma Pharmaceuticals PLC

Headquarters
London, UK
Focus
Pharmaceutical manufacturer
Scale
Global

Markets betamethasone acetate injectables

#13

Fresenius Kabi AG

Headquarters
Bad Homburg, Germany
Focus
Pharmaceutical manufacturer
Scale
Global

Produces betamethasone acetate for hospital use

#14

Aspen Pharmacare Holdings Ltd

Headquarters
Durban, South Africa
Focus
Pharmaceutical manufacturer
Scale
Global

Distributes betamethasone acetate in emerging markets

#15

Glenmark Pharmaceuticals Ltd

Headquarters
Mumbai, India
Focus
Pharmaceutical manufacturer
Scale
Global

Manufactures betamethasone acetate generics

#16

Lupin Ltd

Headquarters
Mumbai, India
Focus
Pharmaceutical manufacturer
Scale
Global

Produces betamethasone acetate for dermatological use

#17

Zydus Lifesciences Ltd

Headquarters
Ahmedabad, India
Focus
Pharmaceutical manufacturer
Scale
Global

Supplies betamethasone acetate in oral and injectable forms

#18

Alkem Laboratories Ltd

Headquarters
Mumbai, India
Focus
Pharmaceutical manufacturer
Scale
Global

Markets betamethasone acetate in India and abroad

#19

Torrent Pharmaceuticals Ltd

Headquarters
Ahmedabad, India
Focus
Pharmaceutical manufacturer
Scale
Global

Produces betamethasone acetate for chronic conditions

#20

Bayer AG

Headquarters
Leverkusen, Germany
Focus
Pharmaceutical manufacturer
Scale
Global

Limited betamethasone acetate portfolio

#21

Johnson & Johnson

Headquarters
New Brunswick, USA
Focus
Pharmaceutical manufacturer
Scale
Global

Produces betamethasone acetate in some formulations

#22

AbbVie Inc

Headquarters
North Chicago, USA
Focus
Pharmaceutical manufacturer
Scale
Global

Markets betamethasone acetate for inflammatory diseases

#23

Eli Lilly and Company

Headquarters
Indianapolis, USA
Focus
Pharmaceutical manufacturer
Scale
Global

Supplies betamethasone acetate in veterinary and human use

#24

Bristol-Myers Squibb Company

Headquarters
New York, USA
Focus
Pharmaceutical manufacturer
Scale
Global

Limited betamethasone acetate production

#25

Shanghai Pharmaceuticals Holding Co., Ltd

Headquarters
Shanghai, China
Focus
Pharmaceutical manufacturer
Scale
Regional

Chinese producer of betamethasone acetate

#26

Zhejiang Xianju Pharmaceutical Co., Ltd

Headquarters
Taizhou, China
Focus
API manufacturer
Scale
Regional

Major Chinese API supplier of betamethasone acetate

#27

Tianjin Tianyao Pharmaceuticals Co., Ltd

Headquarters
Tianjin, China
Focus
Pharmaceutical manufacturer
Scale
Regional

Produces betamethasone acetate for domestic market

#28

Hubei Biocause Pharmaceutical Co., Ltd

Headquarters
Wuhan, China
Focus
API manufacturer
Scale
Regional

Supplies betamethasone acetate intermediates

#29

Crystal Pharma (a division of Chemi SpA)

Headquarters
Milan, Italy
Focus
API manufacturer
Scale
Regional

European producer of betamethasone acetate API

#30

Symbiotec Pharmalab Pvt. Ltd

Headquarters
Indore, India
Focus
API manufacturer
Scale
Regional

Specializes in betamethasone acetate and other steroids

Loading Reviews content from Store report…
Loading Dashboard content from Store report…
Loading Macro Indicators content from Store report…

Recommended posts

Market Intelligence

Free Data: Betamethasone Acetate – World

Instant access. No credit card needed

Sign in for free